85%Confidence
0Views
FDASource
2026-04-06Date
Summary
Cipla's Nilotinib Capsules recall due to stability failures indicates potential quality control issues at manufacturing sites, which could impact patient safety and regulatory standing. This may lead to supply disruptions for this cancer medication and increased scrutiny of Cipla's US operations.
Actionable: Monitor Cipla's regulatory compliance status and consider alternative suppliers for Nilotinib Capsules.
AI Confidence: 85%
Data Points
firmCipla USA, Inc.
classificationClass III
statusOngoing
distributionU.S.A. Nationwide
productNilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now